AbbVie reported robust Q1 2026 results, achieving $15 billion in revenue, a 12.4% increase year-over-year, driven by a 30.9% surge in sales of its immunology drug Skyrizi to $4.48 billion. The strong performance led AbbVie to raise its earnings per share guidance, supported by Skyrizi's clear efficacy advantage and expanding indications despite competition from new oral drugs like Icotyde. Trading at a reasonable valuation with a 14.2x 2026 EPS multiple and a PEG ratio of 0.84, AbbVie offers attractive value amid projected 17% earnings growth and a $250 price target. Risks include pricing pressures, product concentration, and pipeline execution, but current market skepticism presents a buying opportunity.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
